loading
Schlusskurs vom Vortag:
$3.84
Offen:
$3.8
24-Stunden-Volumen:
2.93M
Relative Volume:
0.63
Marktkapitalisierung:
$1.01B
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-13.75
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-0.77%
1M Leistung:
+4.62%
6M Leistung:
+61.09%
1J Leistung:
+178.99%
1-Tages-Spanne:
Value
$3.7847
$4.04
1-Wochen-Bereich:
Value
$3.77
$4.04
52-Wochen-Spanne:
Value
$1.07
$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Firmenname
Akebia Therapeutics Inc
Name
Telefon
617-871-2098
Name
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
181
Name
Twitter
@akebiatx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AKBA's Discussions on Twitter

Vergleichen Sie AKBA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.85 1.02B 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
151.19 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.55 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.65 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.29 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.89 13.23B 2.99B 1.21B 1.13B 25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-04 Fortgesetzt H.C. Wainwright Buy
2025-04-28 Eingeleitet Leerink Partners Outperform
2025-04-01 Eingeleitet Jefferies Buy
2023-11-29 Fortgesetzt BTIG Research Buy
2023-08-28 Hochstufung H.C. Wainwright Neutral → Buy
2023-05-31 Hochstufung Piper Sandler Neutral → Overweight
2022-03-31 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-31 Herabstufung Mizuho Buy → Neutral
2022-03-31 Herabstufung Needham Buy → Hold
2022-03-31 Herabstufung Piper Sandler Overweight → Neutral
2021-03-08 Eingeleitet Cantor Fitzgerald Overweight
2021-01-29 Herabstufung JP Morgan Neutral → Underweight
2019-11-14 Bestätigt Needham Buy
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-07-11 Bestätigt H.C. Wainwright Buy
2019-05-02 Eingeleitet JP Morgan Overweight
2019-03-20 Eingeleitet Citigroup Neutral
2018-09-07 Fortgesetzt Morgan Stanley Equal-Weight
2018-08-10 Bestätigt Needham Buy
2018-06-06 Bestätigt H.C. Wainwright Buy
2017-12-19 Eingeleitet Piper Jaffray Overweight
2017-12-07 Eingeleitet BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-07-10 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt Needham Buy
2016-12-27 Bestätigt H.C. Wainwright Buy
2016-12-20 Bestätigt JMP Securities Mkt Outperform
2016-11-15 Eingeleitet Aegis Capital Buy
2016-09-29 Eingeleitet Brean Capital Buy
2016-03-16 Bestätigt Needham Buy
2016-01-21 Eingeleitet Credit Suisse Neutral
Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

pulisher
Jul 22, 2025

Akebia Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Akebia Therapeutics Inc. stockHigh-octane financial growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $460,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Akebia Therapeutics Inc. stock pricePhenomenal trading returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share - Insider Monkey

Jul 22, 2025
pulisher
Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Is Akebia Therapeutics Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Jul 18, 2025
pulisher
Jul 16, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GATO, AKBA and LCID - ACCESS Newswire

Jul 16, 2025
pulisher
Jul 16, 2025

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

PHD inhibitors reported in Akebia Therapeutics patent - BioWorld MedTech

Jul 16, 2025
pulisher
Jul 14, 2025

Transcript : Akebia Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 10 - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Akebia at H.C. Wainwright: Strategic Insights on Kidney Care Products By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 12, 2025

Akebia Ther stock hits 52-week high at 4.08 USD - Investing.com Australia

Jul 12, 2025
pulisher
Jul 11, 2025

Akebia Ther stock hits 52-week high at 4.08 USD By Investing.com - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 08, 2025

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN

Jul 08, 2025
pulisher
Jul 08, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Upcoming Kidney Disease Conference: Akebia CCO to Share Latest Commercial Strategy - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 07, 2025
pulisher
Jul 03, 2025

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Jul 03, 2025
pulisher
Jul 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 01, 2025
pulisher
Jul 01, 2025

Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan

Jul 01, 2025
pulisher
Jun 30, 2025

12 Small Cap Stocks with High Upside Potential - Insider Monkey

Jun 30, 2025
pulisher
Jun 27, 2025

Wall Street Nears Record Highs Amid Trade Optimism, Jobs Data, and Fiscal Policies in Focus. - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025
pulisher
Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 23, 2025
pulisher
Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks

Jun 13, 2025

Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.34
price up icon 1.09%
$14.93
price up icon 1.70%
$9.24
price up icon 3.82%
drug_manufacturers_specialty_generic RDY
$14.41
price down icon 0.96%
$132.75
price up icon 0.70%
$297.89
price up icon 1.63%
Kapitalisierung:     |  Volumen (24h):